High-dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 5, 2016, Pages

  Farquhar, Cindy ^a   Marjoribanks, Jane ^a   Lethaby, Anne ^a   Azhar, Maimoona ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOLOGOUS BONE MARROW TRANSPLANTATION; BIBLIOGRAPHIC DATABASE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; EVENT FREE SURVIVAL; FEMALE; HUMAN; INTERMETHOD COMPARISON; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; META ANALYSIS; MORTALITY; PROCEDURES; PROGNOSIS; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TIME FACTOR;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84969492095     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003139.pub3     Document Type: Review

References (71)

1. Forbes AJ, Foster E, Lind MJ, Twelves C, Wilson CB, Crown JP, et al. Quality of life in the Anglo-Celtic randomised trial of high dose adjuvant chemotherapy. Breast Cancer Research and Treatment 2001;64(1):129. [Abstract 553]
2. Leonard RCF, Lind M, Twelves C, Coleman R, Van Belle S, Wilson C, et al. Anglo-Celtic Cooperative Oncology Group. Conventional adjuvant chemotherapy versus single-cycle autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomised trial. Journal of the National Cancer Institute 2004;96(14):1076-83.
3. Hurd DD, Peters WP. Randomized, comparative study of high-dose (with autologous bone marrow support) versus low-dose cyclophosphamide, cisplatin, and carmustine as consolidation to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for patients with operable Stage II or III breast cancer involving 10 or more axillary lymph nodes (CALGB Protocol 9082). Journal of the National Cancer Institute Monographs 1995;19:41-4.
4. Marks LB, Cirrincione C, Fitzgerald TJ, Laurie F, Glicksman AS, Vredenburgh J, et al. Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of cancer and leukemia group B protocol 9082. International Journal of Radiation Oncology Biology Physics 2010;76(5):1305-13.
5. Peppercorn J, Herndon J, Kornblith AB, Peters W, Ahles T, Vredenburgh J, et al. The Cancer and Leukaemia Group B (CALGB) and The Southwestern Oncology Group (SWOG). Quality of life among patients with stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy. Cancer 2005;104(8):1580-9.
6. Buijs C, Rodenhuis S, Seynaeve CM, Van Hoesel QG, Van der WE, Smit WJ, et al. Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life. Journal of Clinical Oncology 2007;25(34):5403-9.
7. Cottu OH, Cuvier C, Laurence V, Espié M. High-dose adjuvant chemotherapy for breast cancer: state of the art. Cancer Futures 2001;12(1):27-30.
8. De Vries EGE, Mastenbroek CC, Rodenhuis S. High-dose chemotherapy for breast cancer. Annals of Internal Medicine 1997;126(11):917-8.
9. Nieboer P, De Vries EGE, Mulder NH, Rodenhuis S, Bontenbal M, Van der Wall E, et al. Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients. Bone Marrow Transplantation 2008;42(7):475-81.
10. Rodenhuis S, Bontenbal M, Beex LVAM, Wagstaff J, Richel DJ, Nooij MA, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. New England Journal of Medicine 2003;349(1):7-15.
11. Rodenhuis S, Bontenbal M, Van Hoesel QGCM, Smit WM, Nooij MA, Voest EE, et al. Netherland Working Party on Autologous Transplantation in Solid Tumours. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Annals of Oncology 2006;17(4):588-96.
12. Schagen SB, Muller MJ, Boogerd W, Rosenbrand RM, van Rhijn D, Rodenhuis S, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Annals of Oncology 2002;13(9):1387-97.
13. Van Dam FSAM, Schagen SB, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuyn ME, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. Journal of the National Cancer Institute 1998;90(3):210-7.
14. Rodenhuis S, Richel DJ, Van der Wall E, Schornagel JH, Baars JW, Koning CCE, et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 1998;352:515-21.
15. Schrama JG, Faneyte IF, Schornagel JH, Baars JW, Peterse JL, Van de Vijver MJ, et al. Randomized trial of high dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Annals of Oncology 2002;13(5):689-98.
16. Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. New England Journal of Medicine 2003;349(1):17-26.
17. Scherwath A, Mehnert A, Schleimer B, Schirmer L, Fehlauer F, Kreienberg R, et al. Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Annals of Oncology 2006;17(3):415-23.
18. Zander AR, Krüger W, Schmoor C, Kröger N, Möbus V, Frickhofen N, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. Journal of Clinical Oncology 2004;22(12):1-11.
19. Zander AR, Schmoor C, Kröger N, Krüger W, Möbus V, Frickhofen N, et al. Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up. Annals of Oncology 2008;19(6):1082-9.
20. Colleoni M, Sun Z, Martinelli G, Basser RL, Coates AS, Gelber RD, et al. International Breast Cancer Study Group. The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Annals of Oncology 2009;20(8):1344-51.
21. International Breast Cancer Study Group. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. Journal of Clinical Oncology 2006;24(3):370-8.
22. Coombes RC, Howell A, Emson M, Peckitt C, Gallagher C, Bengala C, et al. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. Annals of Oncology 2005;16(5):726-34.
23. Tokuda Y, Tajima T, Narabayashi M, Takeyama K, Watanabe T, Fukutomi T, et al. Randomized phase III study of high-dose chemotherapy (HDC) with autologous stem cell support as consolidation in high-risk postoperative breast cancer: Japan Clinical Oncology Group (JCOG9208). Poster Presentation: Asco Online: www.asco.org/. American Society of Clinical Oncology, 2001 (Accessed 24th July 2002).
24. Tokuda Y, Tajima T, Narabayashi M, Takeyama K, Watanabe T, Fukutomi T, et al. Autologous Bone Marrow Transplantation Study Group, Breast Cancer Study Group of the Japan Clinical Oncology Group (JCOG). Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208. Cancer Science 2008;99(1):145-51.
25. Cottu PH, Cuvier C, Laurence V, Espié M. High-dose adjuvant chemotherapy for breast cancer: state of the art. Cancer Futures 2001;12(1):27-30.
26. Gianni A, Bonadonna G. Five-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with>3 positive nodes (LN+). Asco Online: www.asco.org/. American Society of Clinical Oncology, 2001 (Accessed 27the June 2002).
27. Gianni AM, Bonadonna G, Michelangelo Cooperative Group. Updated 12-year results of a randomized clinical trial comparing standard-dose to high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with more than three positive nodes (LN+). Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition);25(18S (June 20 Supplement)):549.
28. Hanrahan EO, Broglio K, Frye D, Buzdar AU, Theriault RL, Valero V, et al. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma. Cancer 2006;106(11):2327-36.
29. Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. Journal of the National Cancer Institute 2000;92(3):225-33.
30. Moore HCF, Green SJ, Gralow JR, Bearman SI, Lew D, Barlow WE, et al. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. Journal of Clinical Oncology 2007;25(13):1677-82.
31. NCT00002772 . NCI high priority trial: Phase III randomized study of intensive sequential doxorubicin, paclitaxel and cyclophosphamide versus doxorubicin and cyclophosphamide followed by STAMP I and STAMP V combination chemotherapy with autologous stem cell rescue in women with primary breast cancer and at least 4 involved axillary lymph nodes. https://clinicaltrials.gov/ct2/show/NCT00002772. National Cancer Institute, 2001 (Accessed 21st June 2002).
32. Marino P, Roche H, Biron P, Janvier M, Spaeth D, Fabbro M, et al. Deterioration of quality of life of high-risk breast cancer patients treated with high-dose chemotherapy: The PEGASE 01 quality of life study. Value in Health 2008;11(4):709-18.
33. Roche H, Viens P, Biron P, Lotz JP, Asselain B, PEGASE Group. High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control 2003;10(1):42-7.
34. Gluz O, Mengele K, Schmitt M, Kates R, Diallo-Danebrock R, Neff F, et al. Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. Journal of Clinical Oncology 2009;27(36):6144-51.
35. Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, Jackisch C, et al. West German Study Group. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 2005;366(9501):1935-44.
36. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, et al. Tailored fluorouracil, epirubicin and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. The Lancet 2000;356(9239):1384-91.
37. Brandberg Y. Scandinavian Breast Cancer study group: Quality of life in women with breast cancer randomised to adjuvant treatment with marrow supported high dose chemotherapy with Ctcb (Bmt) or tailored FEC therapy: The SBG 9401 study, Radiumhemmet, Karolinska Hospital. Asco Online: www.asco.org. American Society of Clinical Oncology, 2000 (Accessed 24th July 2002).
38. Wilking N, Lidbrink E, Wiklund T, Erikstein B, Lindman H, Malmström P, et al. Scandinavian Breast Group, study SBG 9401. Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Annals of Oncology 2007;18(4):694-700.
39. Bezwoda W. Randomised, controlled trial of high dose chemotherapy (HD-CNVp) versus standard dose (CAF) chemotherapy for high-risk, surgically treated, primary breast cancer. Asco Online: www.asco.org. American Society of Clinical Oncologists, 1999 (Accessed 29th August 2002).
40. Sportès C, Steinberg SM, Liewehr DJ, Gea-Banacloche J, Danforth DN, Avila DN, et al. Strategies to improve long-term outcome in stage IIIB inflammatory breast cancer: multimodality treatment including dose-intensive induction and high-dose chemotherapy. Biology of Blood and Marrow Transplantation 2009;15(8):963-70.
41. Isaacs RE, Adkins DR, Spitzer G, Freeman S, Pecora AL, Weaver C. A phase III multi-institution randomized study comparing standard adjuvant chemotherapy to intensification with high-dose chemotherapy (HDC) and autologous peripheral blood progenitor cell (PBPC) rescue in patients with stage II/IIIA breast cancer with 4-9 involved axillary lymph nodes. Asco Online: www.asco.org/. American Society of Clinical Oncology, 1999 (Accessed 24th July 2002).
42. Nabholtz JM (PI). A multicenter phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) with TAC followed by high dose chemotherapy with mitoxantrone, cyclophosphamide and vinorelbine (HDCT) with autologous peripheral stem cell transplantation and G-CSF in adjuvant treatment of operable breast cancer with 4 or more positive axillary nodes. http://www.trioncology.org/studies/bcirg-002/. Breast Cancer International Research Group, (Accessed 25th June 2002).
43. Pouillart P (PI). Randomized multicentric exploratory study phase III evaluating the contribution of the therapeutic intensification with autotransplantation of hematopoietic cells in non metastatic breast cancer with ganglionic invasion [Etude prospective multicentrique randomisée de phase III évaluant l'apport de l'intensification thérapeutic avec autotransplantation de cellules hématopoïétiques dans les cancers du sein non métastasés avec envahissement ganglionnaire (N=8)]. FNCLCC website: www.fnclcc.fr. Fédération Nationale des Centres contre le Cancer, 2002 (Accessed 20th August 2002).
44. Roche H, Viens P, Biron P, Lotz JP, Asselain B, PEGASE Group. High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control 2003;10(1):42-7.
45. Nieto Y, Champlin RE, Wingard JR, Vredenburgh JJ, Elias AD, Richardson P, et al. Status of high-dose chemotherapy for breast cancer: a review. Biology of Blood and Marrow Transplantation 2000;6(5):476-95.
46. West German Cancer Center of Essen [pers comm]. [Personal communication]. Personal communication with Regina Schleucher 26th July 2003.
47. IBMTR [pers comm]. Autologous Bone Marrow Transplant Registry: www.ibmtr.org. Melodee Nugent, personal communication with Cindy Farquar 16th May 2002.
48. American Cancer Society. Breast cancer facts and figures. American Cancer Society website: www.cancer.org 2002 (Accessed 6th September 2002).
49. Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP, et al. A phase II study of high dose cyclophosphamide, thiopeta and carboplatinum with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy. Journal of Clinical Oncology 1992;10(1):102-10.
50. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, et al. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. Journal of Clinical Oncology 2011;29(24):3214-23.
51. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. European Journal of Cancer 2002;38(1):99-166.
52. Early Breast Cancer Trialists' Collaborative Group. Multi-agent chemotherapy for early breast cancer. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD000487.pub2]
53. National Health Service. Cancer Screening Programmes. Department of Health website: www.cancerscreening.nhs.uk. Department of Health, 2002 (Accessed 6th September 2002).
54. Eddy DM. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. Journal of Clinical Oncology 1992;10(4):657-70 [Erratum in: Journal of Clinical Oncology 1992 Oct;10(10):1655-8].
55. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer 2015;136(5):E359-86.
56. Frei E III, Canellos GP. Dose: A critical factor in cancer chemotherapy. American Journal of Medicine 1980;69(4):585-94.
57. Gluz O, Mengele K, Schmitt M, Kates R, Diallo-Danebrock R, Neff F, et al. Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. Journal of Clinical Oncology 2009;27(36):6144-51.
58. GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University, 2015 (developed by Evidence Prime, Inc.). Available from www.gradepro.org.
59. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
60. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
61. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. Journal of Clinical Oncology 1986;4(8):1162-70.
62. Mantel N, Haenszel WH. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 1959;22(4):719-48.
63. Nemoto T, Vana J, Bedwani R, Baker HW, McGregor FH, Murphy GP. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer 1980;45(12):2917-24.
64. Nieto Y, Champlin RE, Wingard JR, Vredenburgh JJ, Elias AD, Richardson P, et al. Status of High-Dose Chemotherapy for Breast Cancer: A Review. Biology of Blood and Marrow Transplantation 2000;6(5):476-95.
65. Pedrazzoli P, Martino M, Delfanti S, Generali D, Giovanni Rosti G, Bregni M, et al. European Group for Blood and Marrow Transplantation (EBMT), Solid Tumor Working Party. High-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk primary breast cancer. Journal of the National Cancer Institute. Monographs 2015;2015(51):70-5.
66. Peters WP, Shpall EJ, Jones RB, Olsen GA, Bast RC, Gockerman JP, et al. High dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. Journal of Clinical Oncology 1988;6(9):1368-76.
67. Wang J, Zhang Q, Zhou R, Chen B, Ouyang J. High-dose chemotherapy followed by autologous stem cell transplantation as a first-line therapy for high-risk primary breast cancer: a meta-analysis. PLoS ONE 2012;7(3):e33388.
68. World Health Organization. Globocan. www-depdb.iarc.fr/who/menu.htm 2000 (Accessed 19th May 2003).
69. Williams SF, Gilewski T, Mick R, Bitran JD. High dose consolidation therapy with autologous stem cell rescue in Stage IV breast cancer: A follow-up report. Journal of Clinical Oncology 1992;10(11):1743-7.
70. Farquhar C, Basser R, Marjoribanks J, Lethaby A. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD003139]
71. Farquhar C, Marjoribanks J, Basser R, Lethaby A. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD003139.pub2]